📖
EpiDirect enables rapid bisulfite-free MGMT promoter methylation testing in IDH-wildtype glioblastoma with high agreement across established assays.
Németh A, Selignow C, May A, Schmid K, Dohmen H, Stein M, Trautner J, Haag D, Sahm F, Acker T

EpiDirect enables rapid bisulfite-free MGMT promoter methylation testing in IDH-wildtype glioblastoma with high agreement across established assays.

Medicine & Health Published 2026 Verification Pending

Overview & Synopsis

Open access biomedical research article published in Neurooncol Adv.

Advertisement
SPONSOR CONTENT
Indexed from repository: PubMed Central (pmc.ncbi.nlm.nih.gov)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title EpiDirect enables rapid bisulfite-free MGMT promoter methylation testing in IDH-wildtype glioblastoma with high agreement across established assays.
Author / Organization Németh A, Selignow C, May A, Schmid K, Dohmen H, Stein M, Trautner J, Haag D, Sahm F, Acker T
Subject & Discipline Neurooncol Adv
Categories Medicine & Health
Publication Year 2026
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website PubMed Central (pmc.ncbi.nlm.nih.gov)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-80184
Original Source Link Visit Source Page on pmc.ncbi.nlm.nih.gov »